Chen Ting, Chen Hao, Yan Wei-Hong, Zhu Meng-Yang
Third Hospital of Shanxi Medical University,Shanxi Bethune Hospital,Shanxi Academy of Medical Sciences,Tongji Shanxi Hospital,Taiyuan 030032,China.
Tongji Hospital,Tongji Medical College,Huazhong University of Science andTechnology,Wuhan 430030,China.
Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2023 Jun;45(3):484-492. doi: 10.3881/j.issn.1000-503X.15244.
Parkinson's disease(PD)is the second most common neurodegenerative disease after Alzheimer's disease,with high morbidity and high disability rate.Since the early symptoms of PD are not typical and often similar to those of normal aging or other diseases.It is easy to missed diagnosis and misdiagnosis,which seriously affects the diagnosis and treatment of this disease and aggravetes the burden on the patients' life.MicroRNAs(miRNA)are a class of endogenous non-coding RNAs that are involved in post-transcriptional regulation by binding to target messenger RNAs(mRNA).They are highly conserved,short,easy to obtain,and can stably exist in peripheral body fluids.They have been used as biomarkers for a variety of diseases.Recent studies have demonstrated that miRNA play an important role in the development of PD.This paper reviews the recent research progress of miR-7/124/155,three mature miRNA in PD,aiming to provide reference for clarifying the pathogenesis and guiding the diagnosis and treatment of PD.
帕金森病(PD)是仅次于阿尔茨海默病的第二常见神经退行性疾病,发病率和致残率都很高。由于帕金森病的早期症状不典型,且常与正常衰老或其他疾病的症状相似,容易漏诊和误诊,这严重影响了该病的诊断和治疗,加重了患者的生活负担。微小RNA(miRNA)是一类内源性非编码RNA,通过与靶信使RNA(mRNA)结合参与转录后调控。它们高度保守、短小、易于获取,且能稳定存在于外周体液中,已被用作多种疾病的生物标志物。最近的研究表明,miRNA在帕金森病的发生发展中起重要作用。本文综述了miR-7/124/155这三种成熟miRNA在帕金森病中的最新研究进展,旨在为阐明其发病机制及指导帕金森病的诊断和治疗提供参考。